FDA Approves New Drug to Protect Babies From RSV
On July 17, the U.S. Food and Drug Administration (FDA) approved AstraZeneca and Sanofi's respiratory syncytial virus (RSV) drug, Nirsevimab, for infants. A panel of FDA advisers had recommended the new form of immunization in June. Clinical trials demonstrated that single-dose nirsevimab was 83.2% effective in reducing RSV hospitalizations. Doctors will now have two options for protecting infants against RSV. Previously, at-risk infants and young children were treated with monthly injections of palivizumab, an antibody drug. In August, a Centers for Disease Control and Prevention panel will formally vote on nirsevimab.
Read more on CBS News.